Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia.

@article{Vigan2009InvolvementOT,
  title={Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia.},
  author={Daniela Vigan{\`o} and Cinzia Guidali and Stefania Petrosino and Natalia Realini and T Rubino and Vincenzo Di Marzo and Daniela Parolaro},
  journal={The international journal of neuropsychopharmacology},
  year={2009},
  volume={12 5},
  pages={599-614}
}
Recent advances in the neurobiology of cannabinoids have renewed interest in the association between cannabis and schizophrenia. Our studies showed that chronic-intermittent phencyclidine (PCP) treatment of rats, an animal model of schizophrenia-like cognitive deficit, impaired recognition memory in the novel object recognition (NOR) test and induced alterations in CB1 receptor functionality and in endocannabinoid levels mainly in the prefrontal cortex. In this region, we observed a significant… CONTINUE READING